Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Given Average Recommendation of “Moderate Buy” by Brokerages

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.20.

WHWK has been the subject of several recent research reports. Citizens Jmp started coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 target price for the company. B. Riley Financial assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings cut shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, June 5th. Oppenheimer restated an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Finally, Citigroup assumed coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued an “outperform” rating for the company.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of WHWK. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter worth approximately $28,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics in the 1st quarter valued at approximately $40,000. Dimensional Fund Advisors LP acquired a new stake in shares of Whitehawk Therapeutics in the 3rd quarter valued at approximately $84,000. Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics in the third quarter valued at $159,000. Finally, Marshall Wace LLP bought a new position in shares of Whitehawk Therapeutics in the fourth quarter valued at $164,000. 52.08% of the stock is currently owned by institutional investors.

Whitehawk Therapeutics Stock Down 3.1%

NASDAQ:WHWK opened at $3.71 on Friday. Whitehawk Therapeutics has a twelve month low of $1.57 and a twelve month high of $5.49. The business has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $3.69. The company has a market cap of $183.46 million, a P/E ratio of -2.21 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. As a group, analysts anticipate that Whitehawk Therapeutics will post -1.37 earnings per share for the current fiscal year.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.